H1N1疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：依給藥途徑、品牌類型、分銷管道、地區和競爭格局分類，2021-2031年

全球 H1N1 疫苗市場預計將從 2025 年的 101.3 億美元成長到 2031 年的 130.7 億美元，複合年成長率為 4.34%。

這些疫苗通常以三價或四價季節性疫苗的形式提供，是一種能夠活化免疫系統產生針對H1N1甲型流感病毒亞型的抗體的生物製藥。市場成長的主要驅動力是各國政府積極的免疫接種政策以及各國為應對可能引發大流行的呼吸道感染疾病威脅而維持戰略儲備的需求。世界衛生組織（世衛組織）報告稱，2025年全球季節性流感疫苗的年產能穩定在約15.3億劑，凸顯了為滿足這些公共衛生需求所做的巨大生產努力。然而，由於傳統的雞蛋培養方法勞動密集且耗時，這種強大的生產能力面臨著許多挑戰。這些方法造成了物流方面的限制，阻礙了在突發疫情期間快速擴大疫苗供應，並限制了業界對不斷變化的需求的反應能力。

市場促進因素

全球H1N1疫苗市場的主要成長要素是疫苗研發技術的進步。製造商正從傳統的雞蛋培養方法轉向mRNA和細胞培養等先進平台。這種轉變對於提高疫苗效力和加快生產速度至關重要，尤其是在流行病毒株與疫苗病毒之間存在差異的情況下。具體而言，mRNA技術能夠快速適應病毒變異，與傳統方法相比，可提供更優的預防效果。例如，Moderna公司於2025年6月報告稱，其mRNA-1010候選疫苗在一項針對50歲及以上成年人的3期臨床試驗中，對甲型H1N1流感病毒的相對有效率達到29.6%。此類創新不僅改善了臨床療效，還刺激了市場競爭，並鼓勵對更先進的生產設施進行投資。同時，H1N1感染病例的增加及其對醫療衛生系統的影響，使得各國政府擴大免疫接種目標和進行策略性儲備變得至關重要。嚴重的季節性疫情再次爆發往往伴隨著高住院率。美國疾病管制與預防中心（CDC）2025年7月發布的數據顯示，2024-2025流感季美國將有超過60萬人住院，創15年來新高。這凸顯了大力開展疫苗接種工作以應對公共衛生緊急事件的必要性。這種巨大的流行病學壓力確保了大型公司穩定的收入，儘管需求會隨著季節性疫情的嚴重程度而波動。例如，根據2025年11月的報告，賽諾菲公司2025年第三季的流感疫苗和新冠疫苗銷售額達到15.3億歐元。

市場挑戰

全球H1N1疫苗市場擴張的一大障礙是依賴耗時的雞蛋培養法。這種傳統方法通常需要超過六個月的漫長前置作業時間，用於採購無病原體雞蛋和培養病毒，導致供應鏈柔軟性，無法快速回應需求的快速變化。因此，一旦出現意外疫情爆發或病毒株不匹配需要快速更新疫苗時，該產業將面臨巨大的物流挑戰。無法快速擴大生產規模會導致嚴重的供不應求，限制收入，並使製造商無法在需求高峰期充分利用市場機會。這種傳統技術的廣泛應用進一步加劇了市場柔軟性的不足。歐洲疫苗協會在2025年報告中指出，全球超過80%的季節性流感疫苗和大流行性流感疫苗仍採用傳統的雞蛋培養法。這種對緩慢生產平台的過度依賴限制了整個產業的應對力，使供應鏈更容易受到干擾，並阻礙了更靈活的生產技術的應用。因此，市場成長不斷受到主要生產方式固有的物理和時間限制的阻礙，使其無法充分滿足不斷變化的全球公共衛生需求。

市場趨勢

目前市場趨勢包括研發新冠病毒和H1N1流感聯合疫苗，旨在解決疫苗接種疲勞問題並簡化免疫接種流程。製造商正在整合H1N1抗原和SARS-CoV-2成分，以提供一種在呼吸道疾病爆發期間可有效對抗兩種病毒的單劑量解決方案。這種策略提高了患者的便利性，同時確保對兩種病原體產生強大的免疫反應，這對公共衛生合規至關重要。例如，2025年6月，Novavax公司報告稱，其聯合疫苗候選產品在3期臨床試驗中顯示出強大的免疫反應，抗體水平從基準的2.4倍提高到5.7倍。這凸顯了該行業透過簡化免疫接種流程來涵蓋更廣泛人群的努力。此外，市場正擴大轉向基於細胞培養的生產方式，以避免可能損害疫苗效力的卵母細胞適應性突變。細胞培養平台可防止H1N1病毒在生產過程中發生突變，並確保與野生型株的精確抗原相容性。這比傳統的卵培養方法更具優勢。真實世界數據也支持這項轉變。 CSL Seqirus在2025年10月發布的報告顯示，與雞蛋來源的疫苗相比，細胞培養疫苗在針對經檢測確診的流感病毒的效力方面相對提高了19.8%。這促使業界更多地採用更可靠的非雞蛋來源技術，以確保最佳的抗原真實性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球H1N1疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 給藥途徑（皮內疫苗、肌肉注射疫苗、鼻內疫苗）
  • 按品牌（Agripal、Fioarix、Influgen、Influvac、Nasovac、Vaxigrip）
  • 銷售管道細分（醫院藥局、零售藥局、網路藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美H1N1疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲H1N1疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區H1N1疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲H1N1疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美H1N1疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球H1N1疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AstraZeneca PLC
• Sanofi Pasteur MSD AG
• GSK PLC
• Abbott Laboratories Inc
• CSL Ltd
• Pfizer Inc
• CPL Biologicals Pvt Ltd
• Mitsubishi Tanabe Pharma Corp
• Sinovac Biotech Co Ltd
• Zydus Lifesciences Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global H1N1 Vaccines Market is projected to expand from USD 10.13 billion in 2025 to USD 13.07 billion by 2031, demonstrating a compound annual growth rate of 4.34%. These vaccines, typically found in trivalent or quadrivalent seasonal formulations, are biological agents that prime the immune system to generate antibodies against the influenza A H1N1 virus subtype. The market's growth is primarily fueled by intensive government immunization initiatives and the essential requirement for countries to maintain strategic reserves against respiratory threats with pandemic potential. In 2025, the World Health Organization reported a stable global annual production capacity of around 1.53 billion doses for seasonal influenza vaccines, highlighting the substantial manufacturing effort dedicated to these public health needs. However, this robust capacity faces a significant hurdle due to the laborious and time-consuming nature of traditional egg-based production, which generates logistical constraints that hinder the swift scaling of vaccine availability during unexpected outbreaks and limit immediate industry responsiveness to demand shifts.

Market Driver

A key growth driver for the Global H1N1 Vaccines Market is the progress in vaccine development technologies, as manufacturers shift from conventional egg-based methods towards advanced platforms such as mRNA and cell-based formulations. This shift is crucial for achieving greater efficacy and quicker production, especially when circulating strains differ from the vaccine viruses. Specifically, mRNA technology has allowed for swift adaptation to viral mutations, providing better protection than standard options. Moderna, for example, reported in June 2025 that its mRNA-1010 candidate showed 29.6% relative vaccine efficacy against A/H1N1 in a Phase 3 trial for adults aged 50 and above. These innovations not only improve clinical results but also boost market competition and investment in better manufacturing facilities. Concurrently, the increasing incidence of H1N1 infections and their impact on healthcare systems necessitate expanded immunization coverage and strategic stockpiling by governments. The recurrence of severe seasonal outbreaks, marked by high hospitalization rates-reaching over 600,000 in the US during the 2024-2025 influenza season, a 15-year peak, as per CDC data reported in July 2025-underscores the need for strong vaccination efforts to manage public health emergencies. This significant epidemiological pressure ensures steady revenue for leading companies, though demand can vary with seasonal intensity; for instance, Sanofi's influenza and COVID-19 vaccine sales reached €1.53 billion in Q3 2025, according to a November 2025 report.

Market Challenge

A major impediment to the Global H1N1 Vaccines Market's expansion is its reliance on time-consuming egg-based manufacturing. This conventional method demands extensive lead times, often exceeding six months, for sourcing pathogen-free eggs and culturing the virus, creating an inflexible supply chain incapable of quickly adapting to sudden demand changes. As a result, during unexpected outbreaks or when rapid vaccine updates are needed due to strain mismatches, the industry encounters significant logistical hurdles. This inability to rapidly scale production leads to critical supply shortages, thereby limiting revenue and preventing manufacturers from fully capitalizing on market opportunities during peak demand. The prevalent use of this legacy technology intensifies market inflexibility; Vaccines Europe reported in 2025 that over 80% of global seasonal and pandemic influenza vaccines utilized traditional egg-based production. This heavy dependence on a slow platform restricts the industry's overall responsiveness, making it susceptible to supply chain disruptions and hindering the adoption of more agile manufacturing approaches. Consequently, the market's growth is consistently constrained by the inherent physical and temporal limitations of its main production method, impeding its ability to fully address evolving global public health needs.

Market Trends

Current market trends include the development of combined COVID-19 and H1N1 influenza formulations, which aim to combat vaccine fatigue and simplify immunization efforts. Manufacturers are integrating H1N1 antigens with SARS-CoV-2 components to offer single-dose solutions effective against both viruses during the respiratory season. This strategy improves patient convenience and ensures strong immune responses against both pathogens, vital for public health adherence. For instance, Novavax reported in June 2025 that its combination candidate generated robust immune responses in Phase 3 trials, with antibody levels 2.4 to 5.7 times above baseline. This highlights the industry's dedication to broad population coverage via streamlined vaccination. Furthermore, the market is increasingly shifting towards cell-based manufacturing to avoid egg-adaptive mutations that can compromise vaccine efficacy. Cell-based platforms prevent H1N1 virus mutation during production, ensuring a precise antigenic match to wild-type strains-an advantage over traditional egg-based methods. Real-world data supports this shift, with CSL Seqirus reporting in October 2025 that cell-based vaccines showed a 19.8% relative improvement in effectiveness against test-confirmed influenza compared to egg-based formulations. This drives the industry's adoption of more dependable non-egg technologies to guarantee optimal antigen authenticity.

Key Market Players

• AstraZeneca PLC
• Sanofi Pasteur MSD AG
• GSK PLC
• Abbott Laboratories Inc
• CSL Ltd
• Pfizer Inc
• CPL Biologicals Pvt Ltd
• Mitsubishi Tanabe Pharma Corp
• Sinovac Biotech Co Ltd
• Zydus Lifesciences Ltd

Report Scope

In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

H1N1 Vaccines Market, By Route of Administration

• Intradermal Vaccines
• Intramuscular Vaccines
• Intranasal Vaccines

H1N1 Vaccines Market, By Type of Brand

• Agripal
• Fiuarix
• Influgen
• Influvac
• Nasovac
• Vaxigrip

H1N1 Vaccines Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

H1N1 Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.

Available Customizations:

Global H1N1 Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global H1N1 Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America H1N1 Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Type of Brand
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States H1N1 Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Type of Brand
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada H1N1 Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Type of Brand
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico H1N1 Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Type of Brand
      • 6.3.3.2.3. By Distribution Channel

7. Europe H1N1 Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Type of Brand
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany H1N1 Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Type of Brand
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France H1N1 Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Type of Brand
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom H1N1 Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Type of Brand
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy H1N1 Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Type of Brand
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain H1N1 Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Type of Brand
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific H1N1 Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Type of Brand
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China H1N1 Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Type of Brand
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India H1N1 Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Type of Brand
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan H1N1 Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Type of Brand
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea H1N1 Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Type of Brand
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia H1N1 Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Type of Brand
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa H1N1 Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Type of Brand
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia H1N1 Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Type of Brand
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE H1N1 Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Type of Brand
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa H1N1 Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Type of Brand
      • 9.3.3.2.3. By Distribution Channel

10. South America H1N1 Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Type of Brand
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil H1N1 Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Type of Brand
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia H1N1 Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Type of Brand
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina H1N1 Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Type of Brand
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global H1N1 Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi Pasteur MSD AG
• 15.3. GSK PLC
• 15.4. Abbott Laboratories Inc
• 15.5. CSL Ltd
• 15.6. Pfizer Inc
• 15.7. CPL Biologicals Pvt Ltd
• 15.8. Mitsubishi Tanabe Pharma Corp
• 15.9. Sinovac Biotech Co Ltd
• 15.10. Zydus Lifesciences Ltd

16. Strategic Recommendations

17. About Us & Disclaimer